SELLAS Life Sciences Group, Inc. — Director's Dealing 2022

Mar 15, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELLAS Life Sciences Group, Inc. (SLS)
CIK: 0001390478
Period of Report: 2022-03-14

Reporting Person: Francomano Robert (Chief Commercial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-14	Stock Option (Right to Buy)	$5.23	A	100000	Acquired	2032-03-14	Common Stock (100000)	Direct

Footnotes

F1: One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 14, 2022 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter.